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Abstract
Stem cells represent a unique cell type that is capable of self-renewal and 
differentiation into somatic cell types. Since the derivation of human embryonic 
stem cells and induced pluripotent stem cells, enormous potential has been 
recognized for disease modeling, drug development and regenerative medicine. 
Both embryonic stem cells and induced pluripotent stem cells possess the ability to 
differentiate into all three germ layers, hence they are naturally prone to respond 
to various differentiation stimuli. These inherent cellular fluctuations, which can 
result in risky phenotypic instability, must be addressed prior to introduction of 
these cells to human medicine, since they represent one of the major biosafety 
obstacles in the development of bio-industrial or clinical-grade stem cell cultures. 
Therefore, there is an ongoing need for novel robust, feasible and sensitive meth-
ods for determination and confirmation of the otherwise identical cells status, as 
well as for the detection of hidden divergences from their optimal state. A method 
of choice can be the intact cell mass spectrometry. Here we show how it can be 
applied in routine quality control of embryonic stem cell cultures.
Keywords: intact cell mass spectrometry, whole cell mass spectrometry, embryonic 
stem cells, cell culture, culture adaptation, differentiation, quality control
1. Introduction
Embryonic stem cells (ESCs) emerged as an amazing cell biology phenomenon 
several decades ago. Their derivation represents a milestone in understanding of 
fundamental molecular and cellular processes during early embryonic development, 
as well as differentiation mechanisms in somatic cells. Capacity of self-renewal and 
unlimited differentiation make the human ESCs (hESCs) a promising tool for regen-
erative medicine, tissue engineering, bio-industry, pharmacological modeling and 
pollutant testing. However, in vitro cultured ESCs suffer from inherent instability, 
and may develop unwanted properties over time, such as propensity to cancer devel-
opment or failure of the functional phenotype. Accordingly, the stability of hESCs 
in long term cultures represents an essential prerequisite for a safe use in medical 
or industrial fields. Robust, sensitive and feasible tools are therefore required for 
efficient quality control of ESCs culture.
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The beginnings in Mass Spectrometry (MS) development in biology correspond 
with the discovery of soft ionization techniques, such as Electrospray Ionization 
(ESI) and Matrix-Assisted Laser Desorption-Ionization (MALDI) by John Fenn 
(1988) and Koichi Tanaka (1988), respectively, who have been awarded with the 
Nobel Prize in chemistry in 2002 for these findings. MALDI MS coupled with 
Time-Of-Flight (TOF) analysis has been then successfully introduced to many 
fields beyond analytical chemistry, including proteomics, metabolomics, clinical 
microbiology and structural biology. MALDI TOF MS allows precise identification, 
structural analysis and quantification of various, predominantly soluble, analytes. 
MALDI TOF MS can generate molecular or spectral patterns that can be assigned 
to specific cell types or states, when intact cells are used as the analyte. Moreover 
it provides sufficient discrimination capacity due to a high variability in molecular 
species, constituting the whole spectrum a biomarker even without preceding peak 
identification.
2. Embryonic stem cells and the need of quality control
Shortly after fertilization, early human embryo is composed of blastomeres - 
equal undifferentiated cells, which have an unlimited potential to develop into any 
type of embryonic as well as extraembryonic tissue. When the embryo reaches the 
8-cell stage, its blastomeres start forming intercellular junctions, maximizing the 
contact with each other, in a process called compaction. Already in the 16-cell forma-
tion, called morula, cells with no contact with the outer environment - the inner cell 
mass (ICM) - can be recognized. Prior to implantation, morula develops a small cav-
ity, becoming a blastocyst, in which ICM further proliferates and forms embryoblast. 
Cells of embryoblast, still being pluripotent, differentiate rapidly and build bilaminar 
germ disc with the distinct layers - hypoblast and epiblast. Epiblast cells represent 
the essential developmental source for principal embryonic germ layers - ectoderm, 
mesoderm and endoderm [1].
Mammalian ESCs are derived from undifferentiated ICM of early preimplanta-
tion blastocyst. While the embryoblast represents an ephemeral stage in embryonic 
development, the ESCs, when transferred into long term in vitro culture share some 
characteristics with an immortalized cell line. Specific conditions of the in vitro 
culture prevent differentiation of the ESCs into the embryonic structures, and allow 
ESCs to keep the molecular machinery necessary for the maintenance of pluripo-
tency and unlimited cell divisions [2].
Development of differentiated structures from embryonic precursor cells is a 
tightly regulated process. Pluripotent cells, which have not differentiated properly 
in their developmental time window, or persist ectopically, can form peculiar 
tumors – teratomas. Teratomas contain regions with haphazard accumulation of 
mature tissues, such as hair, cartilage, bone, or teeth. Despite the inherent abnor-
mality of teratomas, they were a unique model, which contributed significantly to 
understanding of embryonic pluripotency and differentiation principles. Indeed, 
the first cell lines that harbored traits of stem cells were derived from mouse 
testicular teratocarcinomas [3]. These cells share many features with primordial 
germ cells, thus they, at the time, served as the first principle model of cell plasticity 
and embryonic differentiation. Genuine embryonic stem cells were derived from 3.5 
dpc mouse blastocyst in 1981 [4], and the long-term culture conditions preventing 
differentiation were adopted from teratocarcinomas culture protocols [5]. Later, 
soluble factors critical for maintaining the pluripotency of mouse ESCs (mESCs), 
e.g. mLIF – mouse leukemia inhibitory factor, and BMP4 – bone morphogenetic 
factor 4, were identified and allowed mESCs propagation [6, 7].
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The embryonic development of primates including humans, however, differs 
from embryonic development of rodents. That is why the derivation of human 
embryonic stem cells has not been achieved until seventeen years later by James 
Thompson [8]. Currently, hundreds of hESC lines and their derivatives are avail-
able through curated stem cell repositories and biobanks [9]. A breakthrough in 
stem cell research came in 2006 when genetic regulators essential for induction of 
pluripotency were discovered by Shinya Yamanaka [10]. These transcription factors 
can reprogram fully differentiated somatic cells, so they obtain undifferentiated 
stem cell-like phenotype. Such human induced pluripotent stem cells (hiPSCs) 
provide a genuine stem cell model with no ethical burden associated with hESCs 
[11]. hiPSCs essentially complement the portfolio of cellular models for description 
of crucial molecular events during embryogenesis, tissue differentiation and cancer 
development. Nowadays, ESCs derived from embryoblasts and hiPSCs derived by 
reprogramming of somatic cells represent an important biological model and hold 
the promise to various clinical applications, including regenerative medicine, tailor-
made cell therapy and drug testing [12, 13].
The state of pluripotency is developmentally unstable and requires specific 
molecular machinery to maintain the stem cell phenotype [14, 15]. Developmental 
trajectories during normal embryogenesis are determined soon, so the complex 
differentiated structures evolve even in a very early embryo. Sophisticated micro-
environment of in vitro cell cultures, which is designed and optimized to stimulate 
unlimited propagation of stem cells and preservation of their full differentiation 
capability [16], is different from the conditions within the developing embryo. 
Protocols which represent the golden standard involve additional “feeder” cell layer, 
which supports cultured stem cells (Figure 1A).
Mouse embryonic fibroblasts (MEFs), human preputial fibroblasts, oviduct 
lining or fetal smooth muscle cells are commonly used as a feeder layer. Feeder cells 
provide necessary intercellular contacts and produce extracellular matrix (ECM) 
along with soluble factors, in order to recreate, to certain extent, the microenviron-
ment of a blastocyst [17]. However, co-culture of hESCs with feeder cells bears the 
risks of carry-over contamination and induction of the immune reaction in a patient 
being exposed to antigens derived from animal feeder layer upon grafting.
Culture protocols with animal additives are therefore not suitable for the direct 
use in humans. hESCs culture on defined surfaces coated with ECM mixtures or 
pure protein layers in complex medium supplemented with essential cytokines 
Figure 1. 
(A) Single colony of hESCs co-cultured with feeder fibroblast layer (MEFs) as visualized by light microscopy. 
(B) Scanning electron micrograph of intact hESCs mixed with matrix containing acidified sinapinic acid and 
spotted on the target plate of the MS instrument.
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(e.g. bFGF, activin) may be a solution, if combined with rigorous quality control of 
other culture parameters (Table 1) [18, 19].
2.1 Phenotype shifts and culture adaptation in hESCs
In prolonged culture, pristine hESCs adapt to a two-dimensional, biochemi-
cally and structurally less complex, in comparison to a blastocyst, microenviron-
ment [20]. However, the introduction into the in vitro culture inevitably induces 
selection: hESCs clones, which fit the artificial culture conditions the best, are 
being preferentially selected. Particularly those are clones which divide regu-
larly with optimal doubling time, show reduced sensitivity to programmed cell 
death, are resistant to passaging method and cell stress arising in culture. Despite 
stringent culture protocols, such clones can acquire non-random chromosomal 
aberrations, alterations of epigenetic landscape and changes in gene expression 
[21–24]. Often, genes which participate in tumor formation or dissemination are 
involved [25], similarly to those in undifferentiated stem cell lines derived from 
teratocarcinomas [26].
Darwinian selection in long-term hESC cultures, accordingly, generates cells 
which remarkably differ from pristine hESCs. Such culture-adapted cells can obtain 
hazardous phenotype [27], which is similar to a malignant cancer cell line, while 
keeping normal levels of transcription factors (e.g. Oct 3/4 and Nanog) and other 
stemness-related molecular markers (e.g. SSEA-4 and Alkaline Phosphatase) [28]. 
Paradoxically, such significant changes in hESCs, which have acquired the adapted 
phenotype, can stay unnoticed if cell morphology or expression of stemness factors 
are not affected. Thus culture-adapted cells can escape routine quality control, 
which is usually based on visual evaluation or monitoring of a several selected 
molecular markers. Incompatible cellular alterations are quickly eliminated in vivo, 
typically by the complete rejection of the embryo. In vitro, however, aberrant clones 
may become dominant in culture and disable the safe use of the particular hESCs 
for clinical or biotechnological applications.
At the moment, there is no routinely applicable method which can reveal 
hidden shifts in hESCs phenotype or to confirm general stability of a cell culture. 
The golden standard for authentication of in vitro cell lines, e.g. ones derived from 
individual patients’ tumors, is based on analysis of short tandem repeats (STRs). 
Repetitive sequences dispersed throughout the genome can provide a unique genetic 
profile and effectively reveal potentially misidentified cell lines [29]. However, 
STRs analysis is uninformative if used for specific cell culture modifications, such 
as co-culture of two cell types, analysis of differentiation stages within a single cell 
line, use of more cell subtypes derived from an individual. Similarly, techniques 
used for analysis of batch to batch variability, purity of cells, genome or proteome 
changes, as well as methods focused on a limited panel of biomarkers are not 
• microbial and viral contamination
• cell line cross-contamination
• carry-over of animal products in culture
• karyotype instability
• activation of oncogenes and risk of tumorigenicity in patient
• acquisition of immunogenicity and risk of graft rejection in patient
• failure of differentiation into functional phenotype
Table 1. 
Risk assessment in clinical grade hESCs culture.
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suitable for quality control in routine applications, because they are not informative 
and often are laborious and costly [30–32].
Successful implementation of pluripotent stem cells into clinical trials requires 
stringent assurance of the cell product quality and safety, including development 
of formal methodology for every step of the cells derivation and culture processes. 
Presence of an unwanted phenotype or deviation from the optimal state of cells 
in culture may inevitably result in failure of the product and a harm to a patient. 
Routinely used methods easily reveal microbial and viral contamination, cell mis-
identifications and chromosomal aberrations which occur in the culture. However, 
subtle phenotypic shifts or unapparent alterations cannot be detected by microscopy, 
narrow focused screening for molecular markers or other conventional methods.
Recently, we have been working on the introduction of techniques used in bioana-
lytical chemistry, chemometrics and in complex data analysis into stem cell field. We 
have demonstrated that method of choice can be the Intact (Whole) Cell MALDI TOF 
Mass Spectrometry coupled with sophisticated statistics. Intact Cell MALDI TOF MS is 
sufficiently robust, sensitive, and cost-effective approach for monitoring of long-term 
cultures stability and differentiation trajectories of ESCs, therefore it has a potential to 
complement the portfolio of quality control tools in clinical or bio-industrial  
applications [33].
3. Intact cell MALDI TOF MS
MALDI TOF MS employs the laser energy to desorb and ionize molecules of an 
analyte from the crystallized mixture with the matrix, and subsequently separates the 
resulting ions according to mass-to-charge (m/z) ratio. The organic matrix enhances 
energy transfer to analyte, preserves the structure of the ionized molecules, e.g. 
peptides, proteins or other biomolecules, and allows their precise structural analysis 
and identification. In cell biology, MALDI TOF MS is one of the preferred methods for 
proteomic analysis in a broad range of samples, such as purified or fractioned extracts 
of cells or tissues. The MS-based proteomics uses protein fragmentation for identifica-
tion and further generation of a list of unique peptide or protein signatures in wide 
range of m/z values [34]. However, the methodological complexity and the character 
of the data output may limit the use of traditional proteomics in routine quality 
control of stem cell cultures, even if coupled with transcriptomics or (meta)genomics.
Even when the intact (whole) cells are used as an analyte, MALDI TOF MS can 
generate rich spectra without the need of previous cell lysis, fractionation or protein 
extraction. Mass spectra contain signals for small proteins and peptides, and a 
variety of other low-mass molecules, including metabolites. Analysis of specific 
spectral (peak) signatures has been successfully introduced to clinical microbiol-
ogy, where MALDI TOF MS enables the rapid discrimination, or “biotyping”, of 
bacterial species without the necessity of complex sample processing [35, 36]. 
Generally the same approach - utilization of relevant spectral patterns as inputs for 
further processing and analysis [33] - can be used for discrimination of cancer cells 
[37, 38] or abnormal stem cells in long-term cultures, even in high-throughput setup 
[39, 40]. Intact Cell MALDI TOF MS was used to identify spectral signatures of glial 
cells and their classification to astrocyte, microglia and oligodendrocyte type [41]. 
Principal component analysis then revealed informative peaks for deeper spatial 
analysis using mass spectrometry imaging in whole brain sections. Similarly, mass 
spectra have demonstrated to contain sufficient information to reveal the immu-
nophenotype and activation state of immune cells, [42–45] or to classify distinct 
mammalian cell lines [46, 47]. Moreover, MS can reveal changes associated with 
molecular phenotype, which occur within cell lines and sublines of common genetic 
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origin. Such approach has been used recently by Povey et al., who demonstrated 
discrimination of neuroblastoma cell lines sensitive to chemotherapy [48], or by 
Cadoni et al. who classified ovarian cancer cells sensitive or resistant to cisplatin, 
based on phospholipid patterns generated by MS [37].
3.1 Intact cell MALDI TOF MS of hESCs
The first step of the preanalytical sample processing is the enzymatic or 
manual harvesting of hESCs under visual microscopic control. Next, cell clusters 
are enzymatically disaggregated and washed in isotonic buffers (e.g. phosphate 
buffered saline, PBS) to remove residual culture medium and additives. PBS has 
been reported not to interfere with MALDI TOF MS significantly [49]. However, we 
observed that it may induce random quenching of ionization and decreased inten-
sity of peaks. Therefore, we have added an additional wash with MS fully compatible 
buffers, such as ammonium acetate [41] or ammonium bicarbonate (ABC) [33], to 
our protocol, to remove traces of PBS in order to improve mass spectra quality. After 
cell number assessment, cell are resuspended in 150 mM ABC to desired concen-
tration. Dry cell pellets can be cryostored (at −80°C or lower) with no significant 
impairment of mass spectra quality.
The MS protocol for hESCs biotyping (fingerprinting) follows the established 
proteomic or microbiological workflow. Dependent on cell type, instrumentation 
type and matrix composition, we use typically 1000-25,000 cells per measurement 
in routine analysis. Cell number can be, though, reduced to several hundred in an 
optimized experimental design. Cells can be directly placed onto a steel target plate 
or on transparent indium-tin oxide (ITO) coated glass slides. The ITO coated glass 
slides enable correlative microscopic analysis in parallel to the MS. In addition, they 
can be used as a substrate for culture of adherent cells [50].
Sinapinic acid (SA) or α-cyano-4-hydroxycinnamic acid (CHCA) acidified with 
trifluoroacetic acid are used as a matrix predominantly. SA and CHCA generate 
uniform-sized crystals, in which cells can be embedded regularly (Figure 1B). 
Although, other matrices, such as 2,5-dihydroxybenzoic acid (DHB) or 2-mer-
captobenzothiazole (MBT) can also provide informative output, they form long, 
needle-like crystals distributed over the target spot unevenly, and therefore are 
more suitable for solubilized samples.
Routinely, we analyze samples in linear positive mode in m/z range of 2-20 kDa, 
using the usual range of laser energy. Some of the dominant peaks, which have 
already been partially identified [41, 47, 51], are regularly observed also in hESCs. 
They correspond to modified histones, thymosin and presumably to ribosomal or 
other small structural proteins, and can provide an immediate verification of mass 
spectrum quality.
Processing of the mass spectrum prior to statistical analysis includes reduction 
of raw data matrix, smoothing of the spectrum, alignment of peaks, baseline sub-
traction and finally detection of peaks. Average spectrum is then calculated from 
technical replicates and used to generate a final dataset of m/z values with assigned 
intensities in mV or relative arbitrary units [33, 52, 53].
4. Data analysis
4.1 Mass spectrum as a biomarker
Mass spectrum recorded in a wide range of m/z values contains hundreds of 
charged molecular entities, which together form a spectral profile, or “fingerprint” 
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that can be uniquely assigned to a specific cell type, phenotype or state. However, 
MALDI TOF mass spectra generated from ionized molecules desorbed from the 
intact cells are complex and depend strongly on the experimental conditions and 
preanalytical errors, such as matrix choice, hardware setup and even operator skills. 
Despite the technical variability, individual mass spectra assembled to a correctly 
processed dataset may serve as input data for sophisticated mathematical analysis. 
After the reduction of the unwanted inconsistency, informative patterns in mass 
spectra can be identified. Finally, processed spectral dataset can be organized in two-
dimensional array of cases and intensities of selected peaks. Before statistical analysis 
is applied to the spectral dataset, preliminary examination of data quality is required. 
Such rigorous control of data quality includes verification of reproducibility, meticu-
lous calibration and elimination of apparent technical errors or outliers.
Mass spectra of complex biological samples usually contain numerous peaks 
with rather low intensities and low signal-to-noise ratio. Therefore, the peak detec-
tion and recognition is dependent on precise calibration. Where appropriate, we do 
recommend using the clusters of isotopically pure elements, such as nanoparticles 
of gold (gold clusters) or black and red phosphorus as calibration standards [54, 55], 
next to commercially available peptide standards. Mono-isotopic calibrants provide 
well defined peaks corresponding accurately to predicted mass, allowing proper 
peaks alignment. Besides, they do not suffer with occasionally problematic indica-
tion of isotopic envelope of high mass peptides or proteins.
For evaluation of mass spectra similarity of technical replicates or experimental 
cohorts, mathematical approaches used in proteomics or metabolomics can be 
applied. Correlation analysis (e.g. Pearson’s correlation, Spearman’s correlation, 
Kendall rank correlation or cosine correlation) can provide a quantitative output 
that can globally evaluate the similarity of mass spectra [56].
Another relevant factor, which can interfere with the outputs of statistical 
analysis, is the presence of outlier values in the dataset (case) or within the mass 
spectrum (peak intensity). Despite the precise laboratory work, outlier values are 
inevitable and are probably associated with stochastic MALDI effects, as have been 
already described in bacterial Intact Cell MS [57]. One of the classical procedures, 
which allows to reveal outliers within the data, is provided by factor analysis and 
includes careful following of the rank of the data matrix by computing eigenvalues. 
The number of non-zero eigenvalues (rank of the matrix), visualized in a scree 
plot, immediately gives the crucial information related to the sample, such as the 
number of recognizable data groups in mass spectra (e.g. cell types or experimental 
conditions). In case of two data groups, the rank should equal to two. The presence 
of outliers is thus indicated by an increased value of the rank [58, 59].
The multivariate evaluation and validation can identify relevant groups or classes 
within the spectral data. The principal component analysis (PCA) and partial least 
squares discriminant analysis (PLS-DA) are commonly used. PCA reduces dimen-
sionality of the spectral data, and defines new vectors - principal components, which 
maximize the variance. Besides, it enables visual observation of the recognized 
groups of the samples. PCA is an unsupervised method with minimal bias, and its 
performance is optimal when the intra-group variability is significantly lower than 
the inter-group variability. It is a well-established tool for processing of complex 
spectral data, e.g. in proteomics or microbiology [60, 61]. PLS uses different math-
ematical model than PCA for the distinction of groups. It represents a supervised 
discriminant analysis, which involves the group information in the algorithm. PLS 
can provide an excellent discrimination, however, it can suffer from inherent ten-
dency to over-fit the data and identify the clusters even in a uniform spectral dataset. 
The validation on independent data is therefore recommended [62]. The workflow of 
data processing in routine analysis of hESCs is summarized in Figure 2.
Mass Spectrometry in Life Sciences and Clinical Laboratory
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4.2 Classification by machine learning
Artificial Neural Networks (ANNs) represent a non-linear mathematical model, 
which resembles a brain neural architecture, and possess “learning” and “general-
ization” abilities. For this reason, ANNs belong to a group of artificial intelligence 
methods with wide spectrum of complex applications, ranging from purely sci-
entific to industrial or clinical. ANNs utilize diverse types of input data, which are 
processed in the context of previous training history on a defined sample database 
to produce a relevant output [64]. The unique chemical fingerprints generated by 
intact cell mass spectrometry allow the ANN to classify the samples even without 
preceeding identification of relevant peaks. Successful application of ANNs or 
any other machine-learning algorithms requires building-up a database of spectral 
patterns specific for individual cell types, phenotypes or states. This has been 
successfully achieved in clinical microbiology, however, in eukaryote biology, the 
Figure 2. 
(A) Example of raw mass spectrum generated from intact cells by MALDI TOF MS, (B) data processing 
workflow, (C) processed mass spectrum, (D) spectral dataset consisting of individual cases (ID1-IDn) and 
assigned values of peak intensities at defined m/z, (E) heat map graphically visualizing the dataset containing 
spectral data of hESCs and four differentiation stages (DIFA-D), (F) example of the output matrix of PCA 
with recalculated coordinates, (G) scree plot visualizing the number of significant factors contributing to the 
variability in the dataset, (H) PCA-based visualization of the differentiation trajectory of hESCs progressing 
towards endodermal phenotype through the four differentiation stages (DIFA-D). Adapted with permission 
from [63].
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complexity of cellular composition and cell plasticity in general represents a major 
issue. Nevertheless, for the “in-house” databases of well-defined cell models and 
conditions of their handling and analysis, the Intact Cell MALDI TOF MS coupled 
with ANNs is a powerful and robust approach that can be easily adapted to any 
specific application (Figure 3).
5.  Applications of intact cell mass spectrometry in quality control of 
embryonic stem cell cultures
Monitoring of clinical-grade stem cells during manipulation, banking or quality 
control by appropriate tools is the essential prerequisite for their application. We 
hypothesized that different cell and tissue types or their different states may vary 
in levels of numerous small molecules, metabolites or peptides and proteins. An 
unambiguous and unbiased chemical fingerprint obtained by MS can thus reflect 
such divergences with high sensitivity. In addition, spectral patterns can serve as a 
highly informative input for subsequent statistical analysis and classification.
To test this hypothesis we used a mouse model of primary hyperoxaluria I - a 
congenital disorder that affect enzymatic machinery of glyoxylate metabolism. 
Primary hyperoxaluria I causes oxalate deposits to localize in liver and kidneys, and 
ultimately lead to hepatorenal failure and extrarenal manifestation of the disease. 
Alterations of chemical composition within the tissue microenvironment of hyper-
oxaluric animals can be translated into specific patterns in mass spectra. A dataset, 
composed of peaks and their corresponding intensities obtained from diseased 
and healthy animals, was used as an input for cluster and classification analysis 
and machine learning (ANN) prediction. Spectral patterns clearly distinguished 
samples from healthy and hyperoxaluric animals and, in parallel, the ANN correctly 
predicted the category based solely on mass spectrum fingerprint [65].
Generally the same approach can be used for rapid discrimination of cells 
occurring in stem cell cultures. Mass spectra from pure populations of mESCs, 
hESCs, and mouse embryonic fibroblasts (MEFs) contain enough information to 
distinguish the cell types by cluster analysis. Interestingly, these spectral profiles 
are not lost even in case of mixed populations of two cell types, such as in cross-
contaminated cell cultures. Therefore, they can serve as a basis for quantitative 
estimation of the individual cell types in the mixture. To model such scenario, a 
broad panel of binary suspension mixtures containing hESCs and MEFs or hESCs 
and mESCs in defined ratios was prepared. Mass spectra were recorded, processed 
and the spectral patterns assigned to known quantities of cells in suspension. 
Resulting dataset then represented calibration data matrix, suitable for quantitative 
Figure 3. 
Architecture of the representative artificial neural network used for prediction of hESC phenotype (output) 
using peak intensities arranged in a defined spectral matrix (input). Adapted with permission from [63].
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prediction by ANNs. Indeed, well-trained and validated network predicted the 
number of contaminating cell type with high accuracy in otherwise homogenous 
and morphologically uniform mixtures. The precision of prediction was dependent 
on a number of peaks and corresponding peak intensities included in the data 
matrix. The apparent, dominant peaks with high intensity, did not contribute 
significantly to the classification. Their exclusion had a negligible effect on the 
ANN performance, suggesting that there is rather a cumulative effect of minor, but 
informative peaks, essential for the analysis output [53].
In the long term cultures of hESCs, abnormal clones with the origin in pristine 
hESCs are inevitably being generated, selected and, finally, expanded. The CCTL 
14 hESC line, which has been propagated over hundreds of passages in vitro suffers 
Figure 4. 
Monitoring of differentiation of hESCs into early lung progenitors (ELEPs) by intact cell MALDI TOF MS. 
hESCs induced to ELEP differentiation lose gradually the gene signatures associated with pluripotency and 
acquire the phenotype of lung progenitors. Differentiation trajectory of cells goes through several immature 
stages and reaches the final, differentiated stage approximately at day 21. Samples for intact cell MALDI TOF 
MS were collected prior to induction of differentiation (hESCs) at days 1, 3, 8 and 10 (D1, D3, D8, D10) and 
finally at the final stage (ELEPs). The lung cancer cell line A549 was used as lung-associated, but abnormal 
sample class. Cluster analysis, such as PCA or a dendrogram, based only on spectral patterns shows clear 
separation of classes and indicate that ELEPs represent indeed a distinct cellular entity [66].
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from chromosomal abnormalities and shows an increased expression of CD30 and 
CD44 surface molecules, previously shown to be associated with acquisition of 
the adapted phenotype and karyotype instability [67]. In addition, adapted, high 
passage hESCs proliferated with reduced doubling time, and showed lower sensitiv-
ity to apoptotic stimuli and decreased capability of differentiation, than pristine 
hESCs. All the low (P29), mid (P72) and high passage (P269) cells maintained 
high and constant expression of stemness markers, e.g. Sox-2, and also share the 
 identical morphology [33].
We recorded mass spectra from intact P29, P72 and P269 hESCs cultured under 
identical conditions, processed and assembled into the dataset containing 255 m/z 
values with assigned peak intensities. The mass spectra showed a high level of 
visual similarity, however the Pearson’s correlation analysis revealed disparities in 
spectral patterns between P29, P72 and P269 cells. Principal component analysis 
then correctly discriminated P29-pristine and P269-adapted cell to individual 
distant cluster, while the P72-transition population cluster has been located and 
scattered between them. Therefore, such a robust dataset of spectral fingerprints 
recorded from intact hESCs contains sufficient information to distinguish normal 
and aberrant cells with otherwise identical morphology and expression of stemness 
markers. Next, we used the same approach to analyze CCTL 14 hESC line stimu-
lated to differentiation. Generally, cell differentiation means acquisition of novel 
phenotypic properties, and morphological hallmarks, as well as various molecular 
mechanisms, involved in cell functioning. Retinoic acid (RA) is a potent inducer of 
embryonic patterning and neurogenesis in vivo, so hESCs induced to the differen-
tiation by RA acquire the neuronal phenotype within several weeks. Mass spectra 
generated from cells treated with RA for only 24 hrs, contained spectral regions 
which allowed detection of such early differentiation events even prior to develop-
ment of clear morphological hallmarks [33].
To test a routine, pre-clinical application, we used Intact Cell MALDI TOF MS 
to monitor the differentiation of hESCs to early lung progenitors (ELEPs). ELEPs, 
being the direct precursors of lung cells (pneumocytes), represent an important 
resource for tissue engineering, pollutant testing and pharmacological analyses. 
ELEPs gradually differentiate from hESCs under specific culture conditions through 
several stages (D1-D10). Differentiating immature cells lack an unambiguous 
marker, which would distinguish them from ELEPs. In addition, during differentia-
tion process aberrant cells with unwanted properties may appear in culture. Intact 
+ Feasible, affordable, and robust technique
+ Intuitive, straight-forward approach
+ Unbiased and marker-free classification
+  Discrimination of unapparent, yet critical alterations in stem or progenitor cells, which are not detectable 
by other techniques
+  Stringent culture protocols and defined SOPs in clinical grade hESCs laboratories allow precise pre-
analytical phase
− Inherent instrumental and technical variability of MALDI TOF MS
− Necessity to build own specialized database of spectral patterns
− Calibration sensitivity
− Nontrivial processing and analysis of complex data
Table 2. 
Advantages (+) and limits (−) of Intact Cell MALDI TOF MS in quality control of hESCs culture in clinical 
grade laboratory.
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Cell MALDI TOF MS was able to distinguish individual immature stages from 
hESCs and from ELEPs, as well as from lung cancer cell line (Figure 4).
In summary, Intact Cell MALDI TOF MS coupled with advanced statistics 
provides an efficient tool for revealing aberrant cells in culture or following differ-
entiation trajectories of pluripotent stem cells and progenitors. The advantages and 
limits of Intact Cell MALDI TOF MS in quality control of clinical grade stem cell 
cultures are summarized in Table 2.
6. Conclusions
Intact Cell MALDI TOF MS reliably discriminates functionally different, but 
otherwise identical types or subtypes of stem cells of common genetic origin. 
Moreover, it reveals aberrant or differentiating clones of clinically relevant stem 
cells or committed tissue progenitors. Coupling the outputs of Intact Cell MALDI 
TOF MS with sophisticated statistics, such as cluster analysis or machine learning, 
may provide a feasible and easy-to-use routine tool for quality control of pluripo-
tent stem cells and progenitors long-term cultures.
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